Table 2.
Results of the primary efficacy and key secondary outcome measures in rimegepant studies.
| Outcome measures | Study 127 | Study 226 | ||
|---|---|---|---|---|
| Rimegepant 75 mg ODT |
Placebo | Rimegepant 75 mg |
Placebo | |
| Pain free at 2 h | n=669 | n=682 | n=537 | n=535 |
| Number (%) | 142 (21.2) | 74 (10.9) | 105 (19.6) | 64 (12.0) |
| p value | – | <0.001 | – | <0.001 |
| MBS free at 2 h | n=669 | n=682 | n=537 | n=535 |
| Number (%) | 235 (35.1) | 183 (26.8) | 202 (37.6) | 135 (25.2) |
| p value | – | 0.0009 | – | <0.001 |
| Sustained pain freedom 2–24 h | n=669 | n=682 | n=537 | n=535 |
| Number (%) | 105 (15.7) | 38 (5.6) | 66 (12.3) | 38 (7.1) |
| p value | – | <0.05 | – | NR |
MBS, most bothersome symptom (i.e. photophobia, phonophobia and nausea); NR, not reported; ODT, orally disintegrating tablet.